Amneal Pharmaceuticals LLC v. Alembic Pharmaceuticals Ltd., 1:26-cv-00798, is a federal Hatch-Waxman patent dispute filed in 2026 between (i) Amneal as the reference-listed drug (RLD) or NDA holder-side party and (ii) Alembic Pharmaceuticals as a generic applicant party. The case is a standard § 271(e)(2) “Orange Book-listed patent” litigation track, but no enforceable, case-specific litigation particulars (asserted patents, claims, paragraph-IV certifications, settlement terms, or briefing posture) are included in the provided prompt. Without those record-level facts, a complete and accurate litigation summary and patent-analytics assessment cannot be produced.
Litigation summary and analysis for Amneal Pharmaceuticals LLC v. Alembic Pharmaceuticals Ltd. (1:26-cv-00798)
No case-specific litigation details are available in the input to support a complete summary or analysis.
What patents are asserted in Amneal v. Alembic (1:26-cv-00798)?
No asserted-patent list is included in the input.
Which Orange Book patents are at issue?
No Orange Book patent numbers, titles, or listed expiration dates are included in the input.
Are the asserted claims method-of-use, formulation, or manufacturing claims?
No claim type breakdown is included in the input.
What type of infringement claim does the complaint allege under 35 U.S.C. § 271(e)(2)?
